Ballicules.com

Leucovorin

WELLCOVORIN

What it isReduced folate bypassing dihydrofolate reductase; methotrexate rescue and fluorouracil potentiation.

Why this oneIt rescues normal cells from methotrexate yet paradoxically strengthens fluorouracil's antitumor effect.

What limits it⚑ Rescue must start on time; delay makes it ineffective. It does not correct renal methotrexate retention.

FDA label

FDA dosingPopulationStartTargetMax
Reduce methotrexate toxicity (impaired MTX elimination)Adults10 mg/m² (up to 25 mg) q6h10 mg/m² (up to 25 mg) q6h until MTX <0.01 µM25 mg q6h (above this, use parenteral)
Folic acid antagonist / DHFR inhibitor overdoseAdults5–15 mg QD5–15 mg QD15 mg QD
FOLR1-CFTD (cerebral folate transport deficiency)<40 kg1–2 mg/kg/dayup to 8.5 mg/kg/day8.5 mg/kg/day
FOLR1-CFTD≥40 kg1–2 mg/kg/dayup to 330 mg/day330 mg/day

Renal Undefined

Hepatic Undefined

For MTX rescue, doses >25 mg q6h require switch to injectable leucovorin.

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy No drug-associated risk identified for intermittent use (antagonist/DHFR toxicity); concomitant chemotherapy may cause fetal harm.

Lactation No data on presence in human milk.

NO BOXED WARNINGS

Principal riskRescue must start on time or it is useless

Cost, est. cash$20–$1,500/dose or month

Generic entry1982

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Leucovorin ballicule

Leucovorin ballicule: receptor binding, kinetics and half-life diagram

Open Leucovorin in the interactive console ↗